ReviewThe Indian journal of medical research2013
Probiotics as efficient immunopotentiators: translational role in cancer prevention.
Review in The Indian journal of medical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02544685 (Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- In vivo effectiveness and safety of probiotics on prophylaxis and treatment of oral candidiasis: a systematic review and meta-analysis.BMC oral health · 2019Pooled it
- Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers.European journal of nutrition · 2017Trial
- Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.Nutrition journal · 2016Trial
- Glycophenotyping of mutants ofApplied and environmental microbiology · 2025Article
- Cyclodextrins as Modulators of Gut Microbiota: Pharmaceutical Applications and Impact on Intestinal Health.Pharmaceutics · 2025Review
- Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy.Frontiers in immunology · 2025Review
- Unraveling the Gut Microbiota: Implications for Precision Nutrition and Personalized Medicine.Nutrients · 2024Review
- Research progress on the microbiota in bladder cancer tumors.Frontiers in cellular and infection microbiology · 2024Review
- Tumor microenvironment signaling and therapeutics in cancer progression.Cancer communications (London, England) · 2023Review
- Recent Perspective ofAntioxidants (Basel, Switzerland) · 2023Review
- The role ofFrontiers in nutrition · 2023Article
- Effect ofNutrients · 2022Article
- Changes in immunological parameters by ageing in rural healthy Indian adults and their associations with sex and lifestyle.Scientific reports · 2022Article
- The Oncobiome in Gastroenteric and Genitourinary Cancers.International journal of molecular sciences · 2022Review
- Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines · 2021Review
- Alleviation of halitosis by use of probiotics and their protective mechanisms in the oral cavity.New microbes and new infections · 2021Review
- Effects ofFrontiers in microbiology · 2021Article
- Update of Probiotics in Human World: A Nonstop Source of Benefactions till the End of Time.Microorganisms · 2020Review
- Immunomodulatory Effect of Lactobacillus casei in a Murine Model of Colon Carcinogenesis.Probiotics and antimicrobial proteins · 2020Article
- Potential Mechanisms of Probiotics Action in the Prevention and Treatment of Colorectal Cancer.Nutrients · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidences indicate that some diseases are triggered by abnormalities of the gut microbiota. Among these, immune-related diseases can be the promising targets for probiotcs. Several studies have proved the efficacy of probiotics for preventing such diseases including cancers, infections, allergies, inflammatory bowel diseases and autoimmune diseases. Lactobacillus casei strain Shirota (LcS) is one of the most popular probiotics, benefits of which in health maintenance and disease control have been supported by several science-based evidences. This review summarizes human clinical trials with this probiotic against cancer development and also discusses the possible immunomodulatory mechanisms by which LcS exerts anti-cancer activity.
Indexed as
Identifiers
24434333PMC3928711What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.